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DDiscussion
Dr Thoralf M. Sundt (Boston, Mass). Congratulations on
conducting what I think is an important study with profound
clinical implications.
Aortic dissection is a highly lethal condition without doubt, and
the results of aortic replacement have improved so much over the
course of the last decade or so that we, as cardiac surgeons, and
cardiac surgeons all around the world have become much more
aggressive about replacing even the moderately dilated aorta.
However, as you have pointed out, the data actually supporting
that practice are pretty thin.
You have chosen to study a population of all patients undergo-
ing aortic valve replacement who have moderate aortic dilatation,
although this is most often discussed in the setting of bicuspid
aortic valve. As you have noted, because BAV is so common,
the recommendations we make concerning the management of
patients with this condition turn out to impact a huge number of
patients.
Your results suggest that we should be more circumspect, that
the moderately dilated aorta need not be routinely replaced. This
is an important and useful counterpoint to the current trend. I
hope there will be a lot of discussion from the floor on this topic
because I do think it is an important one.
There are some challenges in interpreting your study, however,
and I would like to draw attention to several issues and ask several
questions. First, it is challenging any time intellectually, mentally,
when we are comparing 3, rather than just 2, treatment groups.
You have compared the results of AVR alone, AVR with aortic
replacement, and AVR with wrapping. In fact, in the West, aortic
wrapping is seldom, if ever, practiced. In the view of most surgeons
given modern graft material, aortic wrapping offers little advan-
tage over the more definitive procedure of aortic replacement.
So with your permission, I would want to focus only on 2
groups, the groups that we would most commonly deal with in
this country, AVR alone versus AVR with aortic replacement.
That leaves us with 70 patients with aortic replacement and 362
who had AVR alone.
If you focus on these 2 groups, they are of similar age and
similar functional valve pathology, but with female gender much
more common among those with replacement, and BAV almost
twice as common among those with aortic intervention.
Furthermore, the distribution of aortic diameter was actually
much different between these 2 groups, with over 70% of the
patients in the AVR-only group having aortas less than 45 mmThe Journal of Thoracic and Cacompared with less than a third of those in the aortic intervention
group having these small-sized aortas.
In fact, over one-third of the aortic replacement group had an
aorta over 5 cm compared with 4% in the no-aortic intervention
group.
So, my first question really is how do you see these 2 groups as
comparable? Are you not really comparing the outcome of AVR
alone with minimally enlarged aortas in the presence of a trileaflet
valve versus AVR plus aortic replacement in BAV disease?
Dr Kim. Thank you, Dr Sundt, for your important question. I
absolutely agreewith you that maybe 3, and 2, groups are not fairly
comparable because there were significant differences in baseline
profiles in terms of aortic valve morphology and the size of the
aorta.
However, the number of patients in the aorta replacement group
was too small, 70 patients only. Therefore, an adequate statistical
status method, including propensity score matching, was nearly
impossible. We could only obtain less than 50 pairs of patients if
you had a matching technique.
And furthermore, there was only 1 aortic event; therefore,
multivariate analysis was also impossible. Therefore, our study
may be better viewed as a study evaluating the later course of
AVR alone in the moderately dilated ascending aorta, mostly in
40 to 50 mm in our data set, and the second aim may be the
assessment of a safety profile of an additional aortic procedure.
Dr Sundt. I agree with you. I think that the most interesting
group is actually the control group, the AVR-alone group.
Second, there were 13 patients with unknown cause of death.
What happens to your analysis if you assume that all of these
deaths were due to aortic complications? Do you come to the
same conclusion?
Dr Kim. Thank you. Thirteen patients with unknown causes of
death were regarded as cardiac deaths, and when we broke down
the analysis according to the all-cause death and cardiac death,
there were no significant differences among the 3 groups. So I
believe the management strategy did not affect the survival.
Dr Sundt. And, third, there is significant controversy as to
whether the dilated aorta associated with a bicuspid valve is size
for size, diameter for diameter, fundamentally more prone to
complications than the aorta associated with a trileaflet valve.
In your control group, you have 139 patients withBAV.You have
shownwhat appears to be no difference in rate of growth, but just to
emphasize the point, do you see in the control group any evidence
for a difference in behavior at any given diameter between the aorta
associated with a trileaflet valve or a bicuspid valve?
Dr Kim. That is an important point. We try to compare in terms
of aortic events, aortic expansion rate, but we could not find any
significant difference between tricuspid valves and bicuspid.
Even when the analysis was broken down according to the aortic
diameter, we did not find any significant difference between the
2 valve morphology types.
Dr Sundt. Thank you much because I think, regardless of what
the histology shows and the theory may be, the bottom line always
is the clinical behavior. And sowe need these kinds of clinical data
to really know whether we are doing the right thing for our
patients. Thank you.
Dr Kim. Thank you very much.rdiovascular Surgery c Volume 146, Number 4 809
